101
|
Bagot M, Dreno B, Beylot-Barry M, Dalle S. Amélioration de la qualité de vie chez les malades ayant un lymphome T cutané traités par l’anticorps monoclonal anti-CCR4 mogamulizumab versus vorinostat : résultats de l’étude MAVORIC. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
102
|
Faiz S, Carpentier O, Forcade E, Beylot-Barry M, Yakoub Agha I, Fegueux N, Dereure O, Goursaud L, Chevalier P, Huynh A, Rubio MT, Granata A, Charbonnier A, Dulery R, Suarez F, Bay JO, Bagot M, De Masson A, Pefault De Latour R, Magro L, Mortier L. Réinjections de lymphocytes du donneur dans les lymphomes cutanés T : une cohorte rétrospective multicentrique française pour la SFGM-TC et le GFLEC. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
103
|
Gerard E, Dupuis F, Lamant L, Torossian N, Chaltiel L, Filleron T, Beylot-Barry M, Dutriaux C, Prey S, Gros A, Jullie ML, Meyer N, Vergier B. Évaluation des critères cliniques, pathologiques et moléculaires prédictifs de réponse à l’immunothérapie anti-PD1 dans le mélanome métastatique : analyse rétrospective de 70 patients. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
104
|
Masson Regnault M, Castaneda Sanabria J, Tran M, Beylot-Barry M, Bachelez H, Beneton N, Chosidow O, Dupuy A, Joly P, Jullien D, Mahé E, Richard MA, Viguier M, Tubach F, Sbidian E, Paul C. Les patients de la vraie vie peuvent-ils être inclus dans les études cliniques évaluant des biologiques ? Analyse dans la cohorte PsoBioTeq. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
105
|
Bassompierre A, Capelle C, André F, Becquart O, Combermale P, Beylot-Barry M, Guillot B, Mortier L. Traitement intermittent par vismodégib des carcinomes basocellulaires (CBC) avancés : efficacité et tolérance. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.090] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
106
|
Becquart O, Oriano B, Dalle S, Mortier L, Leccia M, Dutriaux C, Dalac S, Lacour JP, De Quatrebarbes J, Brunet-Possenti F, Saiag P, Lesimple T, Beylot-Barry M, Aubin F, Stoebner PE, Lok C, Dreno B, Porcher R, Lebbe C, Bernard G. Tolérance et efficacité en vie réelle des thérapies ciblant la voie des MAPKinases chez les sujets âgés atteints d’un mélanome métastatique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
107
|
Amatore F, Viguier M, Beylot-Barry M, Mahé E, Staumont-Sallé D, Villani A, Picard-Gauci A, Girard C, Sbidian E, Bachelez H, Richard MA. Étude des prescriptions de biosimilaires de l’infliximab dans le psoriasis dans les services de dermatologie français. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
108
|
Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Rotolo F, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Descamps V, Lok C, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Ballon A, Michiels S, Lebbe C, Borget I. Réévaluation de la survie et du coût du mélanome métastatique : estimation à partir de la cohorte MELBASE. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
109
|
Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. 蕈样肉芽肿/ Se´zary综合症中的感染性事件. Br J Dermatol 2018. [DOI: 10.1111/bjd.17300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
110
|
Vigarios E, Beylot-Barry M, Jegou MH, Oberic L, Ysebaert L, Sibaud V. Stomatite sévère induite par l’ibrutinib : première caractérisation. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
111
|
Messagier AL, Cirrotteau P, Dubois A, Gerard E, Doutre MS, Beylot-Barry M, Heron-Mermin D. Un cas de pemphigus superficiel induit par la radiothérapie. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
112
|
Sonigo G, Battistella M, Beylot-Barry M, Oro S, Franck N, Barete S, Bouaziz J, Ram-Wolff C, Boulinguez S, Dereure O, Bachelez H, Bonnet N, Socie G, Brice P, Brunet-Possenti F, Dalle S, Suarez F, Marçais A, Boccara O, Bodemer C, Adamski H, D’Incan M, Fraitag S, Bagot M, Michonneau D, De Masson A. Lymphomes T sous-cutanés à type de panniculite : étude anatomoclinique rétrospective de 55 cas. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
113
|
Tetu P, Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Dalac S, Dutriaux C, Lacour JP, Saiag P, Descamps V, De Quatrebarbes J, Stoebner P, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Dréno B, Mohamed S, Ballon A, Porcher R, Lebbé C. Impact de la radiothérapie cérébrale concomitante chez les patients présentant un mélanome avancé avec métastases cérébrales. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
114
|
Ducharme O, Beylot-Barry M, Pham-Ledard A, Laharanne E, Faur N, Prochazkova-Carlotti M, Vergier B, Merlio JP, Gros A. Identification de marqueurs de réponse au rituximab-polychimiothérapie des lymphomes B cutanés primitifs diffus à grandes cellules de type jambe par analyse protéomique et mutationnelle. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
115
|
Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events in mycosis fungoides/Sézary syndrome. Br J Dermatol 2018. [DOI: 10.1111/bjd.17285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
116
|
Kerneuzet I, Lespagnol A, Rioux-Leclerc N, Dinulescu M, Lesimple T, Dousset L, Gérard E, Beylot-Barry M, Dupuy A, Prey S, Caumont C, Capellen D, Merlio JP, Galibert MD, Boussemart L. Séquençage nouvelle génération (NGS) de mélanomes à partir d’un panel de 315 gènes et 28 introns : intérêt clinique de l’identification de mutations pathogènes hors BRAF/NRAS/KIT dans la vraie vie. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
117
|
Atallah V, Amestoy F, Gerard E, Leduc N, Huchet A, Beylot-Barry M, Dupin C, Prey S, Dousset L, Trouette R, Ouabrache N, Maillot O, Martin M, Gillon P, Dutriaux C, Vendrely V. Concurrent Radiation Therapy for Patients with Metastatic Melanoma and Receiving Anti-Programmed-Death 1 Therapy: A Retrospective Monocentric Study on 141 Patients. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
118
|
Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, Borget I. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. Eur J Cancer 2018; 105:33-40. [PMID: 30384014 DOI: 10.1016/j.ejca.2018.09.026] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Revised: 08/16/2018] [Accepted: 09/24/2018] [Indexed: 01/07/2023]
Abstract
PURPOSE Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which showed significant improvement in survival. In France, in 2004, the cost of MM was estimated at €1634 per patient; this cost has not been re-estimated since. This study provided an update on survival and cost in real-life clinical practice. METHODS Clinical and economic data (treatments, hospitalisations, radiotherapy sessions, visits, imaging and biological exams) were extracted from the prospective MelBase cohort, collecting individual data in 955 patients in 26 hospitals, from diagnosis of metastatic disease until death. Survival was estimated by the Kaplan-Meier method. Costs were calculated from the health insurance perspective using French tariffs. For live patients, survival and costs were extrapolated using a multistate model, describing the 5-year course of the disease according to patient prognostic factors and number of treatment lines. RESULTS Since the availability of new drugs, the mean survival time of MM patients has increased to 23.6 months (95%confidence interval [CI] :21.2;26.6), with 58% of patients receiving a second line of treatment. Mean management costs increased to €269,682 (95%CI:244,196;304,916) per patient. Drugs accounted for 80% of the total cost. CONCLUSION This study is the first that evaluated the impact of immunotherapies and targeted therapies both on survival and cost in real-life conditions. Alongside the introduction of breakthrough therapies in the first and subsequent lines, MM has been associated with a significant increase in survival but also in costs, raising the question of financial sustainability.
Collapse
|
119
|
Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study. Br J Dermatol 2018; 179:1322-1328. [DOI: 10.1111/bjd.17073] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/02/2018] [Indexed: 01/22/2023]
|
120
|
Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Jeudy G, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Ballon A, Porcher R, Lebbe C. Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
121
|
Polivka L, Oubaya N, Bachelez H, Paul C, Richard MA, Beylot-Barry M, Schmutz JL, Beneton N, Mahé E, Viguier M, Chosidow O, Canoui-Poitrine F, Sbidian E. Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015. J Eur Acad Dermatol Venereol 2018; 32:1920-1929. [PMID: 29729123 DOI: 10.1111/jdv.15044] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2018] [Accepted: 03/28/2018] [Indexed: 11/28/2022]
Abstract
BACKGROUND In the late 2000s, the introduction of biologics transformed the prognosis for patients with moderate-to-severe psoriasis. We hypothesized that treatment with biologics may associate with a reduction in the hospitalization rate for psoriasis flares. OBJECTIVE To analyse changes over time in the hospitalization rate for psoriasis flares. METHODS We included inpatient stays in any of nine French hospitals between 2005 and 2015 for a psoriasis flare, as documented in the national inpatient database. In two centres, we also analysed data from the individual patients' electronic medical records. RESULTS A total of 3572 stays were included. The introduction of biologics was not associated with a decrease in the number of hospitalizations for a psoriasis flare; on the contrary, we observed a non-significant increase in the number of hospitalizations (13 hospitalizations for psoriasis flares per quarter per 10 000 beds). In the two-centre study, the introduction of biologics was associated with a significant increase in the hospitalization of patients receiving topical treatments only (520 hospitalizations per year per 10 000 beds) and those with a first psoriasis flare. CONCLUSION The number of hospitalizations for a psoriasis flare tended to increase between 2005 and 2015. The availability of additional treatment options might have increased patient demand and/or broadened the indications in clinical practice.
Collapse
|
122
|
Lamoureux A, Ouhabrache N, Coulibaly S, Dousset L, Gerard E, Dutriaux C, Pham-Ledard A, Cogrel O, Trouette R, Beylot-Barry M, Vendrely V. PO-0835: Contact Radiotherapy For Lentigo Maligna And Lentigo Maligna Melanoma: A Cohort Of 61 Cases. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31145-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
123
|
Samimi M, Dreno B, Aractingi S, Beylot-Barry M, Bodemer C, Chosidow O, Cribier B, Lacour JP, Paul C, Richard MA, Gaudy-Marqueste C, Soria A. [On the attractiveness of a university-hospital career in medicine: Obstacles and solutions. The teachers' perspective]. Ann Dermatol Venereol 2018; 145:196-199. [PMID: 29241631 DOI: 10.1016/j.annder.2017.10.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Accepted: 10/13/2017] [Indexed: 11/29/2022]
|
124
|
Dupin N, Beylot-Barry M. Avant-propos. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
125
|
Gaudy-Marqueste C, Samimi M, Soria A, Aractingi S, Bodemer C, Chosidow O, Cribier B, Lacour JP, Paul C, Richard MA, Beylot-Barry M, Dreno B. [Guide to university hospital careers in dermatology. The GRENT (Graines Engrais Tuteurs - Seed Fertilizer Plant stick) Program]. Ann Dermatol Venereol 2018; 145:200-209. [PMID: 29449018 DOI: 10.1016/j.annder.2017.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|